

Mitsudomi, Tetsuya

Institution/Organization

Kindai University Faculty of Medicine

Primary Specialty

Thoracic Surgery

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

Understood

Disclosure of Potential Conflicts

Understood

COI Disclosure

Disclosures

AstraZeneca: advisory role, speaker fee

MSD: advisor role, speaker fee

Novartis: advisor role, speaker fee

Bristol Myers Squibb: advisor role, speaker fee

Ono: advisor role, speaker fee

Pfizer: advisor role, speaker fee

Boehringer Ingelheim: advisor role, speaker fee

Eli-Lilly: Speaker

Chugai: advisor role, speaker fee

Janssen:

Amgen: advisor role

Daiichi-Sankyo: advisory role

Taiho: advisor, speaker

INVITAE: speaker role

Bayer: speaker

Thermofisher: speaker advisor

COI Disclosure Certification

Disclosed

Confidentiality Agreement

Agree

Standards of Conduct Agreement

Agree

IASLC's Tax-Exempt Status

Agree

COI Follow-Up

Disclose any clinical trials you are conducting for institution fees.

Agean CheckMate 816 Keynote-091 BR.31

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

President, The Japan Lung Cancer Society 2014-2018

Board of Director, Japanese Society of Medical Oncology 2013-2019 Coard of Director, Japanese Association for Chest Surgery 2013-2019

Have you received any personal fees from any outside accreditation entities such as CME companies?

No

Are you conducting clinical trials with any oncology equipment companies?

No